CDT Equity (CDT) Cash from Financing Activities (2022 - 2026)
CDT Equity's (CDT) quarterly Cash from Financing Activities came in at $487000.0 in Q1 2026, down 91.78% YoY from $5.9 million in Q1 2025, and down 72.03% on a QoQ basis from $1.7 million in Q4 2025.
CDT Equity (CDT) Cash from Financing Activities (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Cash from Financing Activities data on file, last reported at $487000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 91.78% year-over-year to $487000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 4.49% YoY) and the FY2025 annual result came in at $17.4 million, up 187.16% from the prior year.
- Cash from Financing Activities fell to $487000.0 in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $136.5 million in Q1 2022 to a low of -$135.0 million in Q3 2022.
- A 5-year average of $2.7 million and a median of $2.0 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 144.37% — and 2024, when it jumped 1116.91%.
- Tracing CDT's Cash from Financing Activities over 5 years: stood at $933000.0 in 2022, then sank by 144.37% to -$414000.0 in 2023, then jumped by 1116.91% to $4.2 million in 2024, then tumbled by 58.65% to $1.7 million in 2025, then tumbled by 72.03% to $487000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $487000.0 (Q1 2026), $1.7 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 1.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.19 Mn |
| Jun 30, 2026 | 1.19 Mn |
| Mar 31, 2026 | 487,000.00 |
| Mar 31, 2026 | 487,000.00 |
| Dec 31, 2025 | 1.74 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 6.00 Mn |
| Sep 30, 2025 | 6.00 Mn |
| Jun 30, 2025 | 3.76 Mn |
| Jun 30, 2025 | 3.76 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | 4.21 Mn |
| Dec 31, 2024 | 4.21 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Dec 31, 2023 | -414,000.00 |
| Dec 31, 2023 | -414,000.00 |
| Sep 30, 2023 | 9.11 Mn |
| Sep 30, 2023 | 9.11 Mn |